Abstract Details

Title Development of a validated Western blot method for quantification of human dystrophin protein used in Phase II and III clinical trials of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD)

Topic Neuromuscular and Clinical Neurophysiology (EMG)

Presentation(s) P5 - (-)

Poster/Presentation
Number 105

Background

Objective

Design/Methods

Results

Conclusions

Authors/Disclosures
F Schnell PRESENTER	No disclosure on file
	No disclosure on file
Johannes Dworzak	No disclosure on file
JS Charleston	No disclosure on file
DE Frank	No disclosure on file
	No disclosure on file
Sarah E. Lewis (Sarepta Therapeutics)	Mrs. Lewis has received personal compensation for serving as an employee of Sarepta Therapeutics . Mrs. Lewis has stock in Sarepta Therapeutics.
	No disclosure on file
Louise R. Rodino-Klapac (Sarepta Therapeutics)	Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care.
Zarife Sahenk, MD, PhD, FAAN (The Research Institute at Nationwide Childrens.org)	Dr. Sahenk has nothing to disclose.